Duchenne muscular dystrophy (DMD) is a degenerative disease caused by mutations in the dystrophin gene that ultimately results in the absence of the functional protein. The number of different mutations, coupled with the sheer size of the dystrophin gene, makes DMD a particularly diffi cult disease for which to develop treatments. While there has been some promise with exon-skipping-based treatments, greatly shortened micro-dystrophin cDNAs, and myoblast transplantation, there still remains the concern that expression of wild-type dystrophin in a DMD patient will be immunogenic and cause corrected fi bers to be destroyed. However, another gene, utrophin, has signifi cant homology to dystrophin, and is not mutated in DMD. Utrophin is widely expressed at the sarcolemma during muscle development, where it fulfi lls the same role as dystrophin. However, utrophin is restricted to the neuromuscular junction in adult muscle. Additionally, the utrophin mRNA has been shown to be translationally repressed by several miRNAs acting on the 3' untranslated region (3'UTR). Thus, we sought to develop a genome engineering-based strategy for a cellular therapy in which the patient's own cells would be modifi ed to produce enough utrophin to repair the dystrophin defi ciency. As a proof-of-principle, we chose to use induced pluripotent stem cells (iPSCs) from the mdx mouse, which is dystrophin-defi cient. We have previously shown that we can reprogram fi broblasts to iPSCs bearing a single copy of our reprogramming cassette, subsequently introduce a transgene, and then excise the reprogramming cassette using a combination of the phiC31 and Bxb1 integrases and Cre resolvase. In this work, we chose peroxisome proliferator-activated receptor gamma coactivator-1 alpha as our transgene because it is a known upregulator of utrophin and has other benefi cial effects. Subsequently, we utilize the CRISPR/ Cas9 system to replace the 3'UTR of utrophin with a GFP-luciferase reporter construct with a different 3'UTR in frame with the utrophin gene, both to relieve translational repression and facilitate tracking of utrophin expression. This strategy is also applicable to human cells. These data demonstrate the feasibility of using genome engineering to exploit and modify transcriptional and translational regulation to generate a cell-based therapy for Duchenne muscular dystrophy. Clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases (RGNs) can robustly and effi ciently induce targeted double-stranded breaks (DSBs) for genome editing. However, previous work from our lab and others has shown that the Streptococcus pyogenes Cas9 nuclease can induce undesired mutations at 'off-target' sites that harbor as many as fi ve mismatches from the intended on-target site. Furthermore, these off-target sites can, in certain cases, be mutagenized with similar (or even higher) frequencies than those observed at the on-target site. To improve our understanding of CRISPR RGN off-target effects in human cells, we have used high-throughput next-generation sequencing to more sensitively quantify these unwanted genomic alterations. Here we report on the identifi cation of novel off-target mutations for Cas9 nucleases targeted to a variety of different endogenous human genes using full-length single guide RNAs (sgRNAs). The results of our experiments expand our understanding of Cas9-mediated off-target mutations in human cells, further characterize the specifi cities of RGNs directed by our recently developed truncated gRNAs (tru-gRNAs), and demonstrate that some standard full-length gRNAs can induce a wider range of off-target Cas9-directed genomic alterations than previously reported.
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The development of targeted double-strand nucleases such as zinc fi nger nucleases, TALENs and CRISPR/Cas has dramatically improved the ease and effi ciency of precise genome modifi cation. The effi ciency is such that they can be used directly in mouse and rat embryos to produce knockout animals and animals carrying small insertions. Larger-scale genome modifi cation, i.e., the insertion or replacement of sequence over distances of more than a few kilobases, still require the modifi cation of cells that can contribute to the germline.
Rat spermatogonial stem cells (SSCs) are a unique population of cells that remain in an undifferentiated, self-renewing state in cell culture, but provide continuous spermatogenesis when transplanted into the testes. Like most tissue culture cells, they are amenable to genetic modifi cation. They thus provide a useful alternative to embryonic stem cells for creating genetically modified rats carrying targeted mutations: the SSCs are modifi ed in vitro and then transplanted into the testes of genetically sterile males, which are then bred to produce animals carrying the desired mutation.
The introduction of an engineered mutation into the genome, especially for gene therapy purposes, requires the inclusion of a selectable marker that then must be removed. The only system available technology that removes the selectable marker without leaving a residual mutation in the genome is the piggyBac (PB) transposon/transposase system.
We describe here the combination of these approaches for the successful replacement of approximately 10 kb of rat sequence with human sequence in SSCs. We combined XTN™ TALENS with a targeting vector incorporating a PB-based Puromycin and HSV-TK selection marker for correct targeting of the genome after positive selection. We then utilized an excision-only PB transposase and Ganciclovir selection for the precise, Footprint-Free™ removal of the selectable marker.
The approach detailed here is applicable to any cell type, and is particularly useful for gene therapy applications where the precise excision of selectable markers is necessary.
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